Media & Insight

Financing growth in the pharmaceutical industry

How Pemberton helped a leading pharmaceutical and biotechnology company grow its core services and expand its development and manufacturing capabilities.


Quotient Sciences is a leading provider of research and development services to pharmaceutical and biotechnology customers around the world.

Dedicated to accelerating the development of new drugs for patients, its services include formulation development, clinical pharmacology and both clinical and commercial manufacturing services.

With over 850 staff based in state-of-the-art manufacturing and clinical facilities in the US and the UK, Quotient’s vision is to transform drug development with science and innovation to accelerate the delivery of new medicines.

Translational Pharmaceutics® is the company’s novel approach to drug development, which reduces costs and shortens timelines by integrating formulation development, real-time adaptive Good Manufacturing Practice (GMP) and clinical research for the continuous improvement of development programmes. On the back of Translational Pharmaceutics®, Quotient has grown significantly in recent years, and now generates annual revenues in excess of £100m.

Fuelling the next stage of growth

As the next step in its impressive growth journey, Quotient planned to broaden its core services as well as expand its formulation development and manufacturing capabilities. To facilitate this, the company undertook a sale process of a majority stake to a company backed by Permira Funds. Pemberton, a key partner to Quotient already, remained in situ to support that growth plan under Permira’s new ownership.

Pemberton’s solution

Pemberton already knew Quotient well, having provided a Term Loan in support of GHO Capital’s acquisition of the business in 2016. Following that transaction, Pemberton provided incremental capital in support of Quotient’s M&A and capex strategy between 2017 and 2018. When it came to the sale to Permira, Pemberton was closely involved in the entire process, initially working together with previous owner, GHO, and management to understand its priorities in the future capital structure under new ownership.

The Quotient credit story is far from straightforward, having expanded both its geographic presence and breadth of services. Pemberton’s familiarity with the company enabled the team to provide expert views as an existing lender with prospective bidders.

Ultimately, Pemberton was able to offer a “staple” financing, providing a certainty that supported the sale process. Once approved, the Pemberton team was able to turn around the financing documentation very swiftly, aiding an efficient transaction. Critically, Pemberton was able to provide the entire debt package for the sale, including ample flexibility around acquisitions to support further growth.

Roberto Biondi, Partner, Permira, said:

“Pemberton’s speed, commitment and confidentiality were instrumental in securing certain funds at attractive terms on a very accelerated timeline.”

Gordon Cameron, Chief Financial Officer, Quotient Sciences, said:

“Pemberton has supported us since 2016 and provided capital for both acquisitions and capital expenditure which helped our rapid growth. We have enjoyed working with Pemberton and felt they always understood our business and strategy, so when Permira decided to buy the business, we had a strong preference to continue our relationship with Pemberton. We were pleased with Pemberton’s speed of execution during a tight M&A process and appreciated their ability to structure the new debt financing to reflect the growth and maturity of the business. We look forward to working with Pemberton over many years to come.”

Contact us

Business Development:
Contact: Antoine Josserand
Tel: +44 (0) 20 7993 9311
Contact: Cary Gibson
Tel: +44 (0) 20 7993 9323
Media Relations:
Contact: Carl Leijonhufvud
Tel: +44 (0) 20 3805 4827
Contact: Viktor Tsvetanov
Tel: +44 (0) 20 3435 7469
> €7.6bn

To access this website, you must agree to the following by indicating your acceptance below.

This website and the information, products and/or services available on or through it are not intended to offer or promote the offer or sale of securities, the securities of any fund or the services of any company, in certain jurisdictions or to certain types of investors. In particular, no securities or investments may be offered or sold, transactions effected or services offered or provided in certain jurisdictions as noted in our Terms of use.

Pemberton Capital Advisers LLP or its affiliates and/or subsidiaries (collectively, Pemberton) may not be registered in a jurisdiction where it is not possible to provide investment advisory services to one or more types of investors, directly in a separately managed account or via a private fund.

This website is directed only at investment professionals, professional clients, persons having professional experience of investing in unregulated schemes, high net worth companies, partnerships, associations or trusts and personnel of any of the foregoing having professional experience of investing in unregulated schemes (each within the meaning of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, the Financial Services and Markets Act 2000 (Promotion of Collective Investment Schemes) (Exemptions) Order 2001 and the UK FCA Handbook, as applicable) and that, in the case of persons outside the United Kingdom, this website is also only directed to persons who may lawfully access it without breach of law or regulation or imposing any requirement on Pemberton or any other person to be licensed, registered or approved in any other jurisdiction. I further understand and acknowledge that no-one else should access the website or act on or otherwise rely on any information in it. Pemberton will not make any investment or investment activity referred to on this website available to any other person.

This website and all materials on it or available via it do not and are not intended to offer for sale or promote the offer for sale of the securities of any private fund in the United States or to a U.S. person as defined in Regulation S under the U.S. Securities Act of 1933 (“Securities Act”), or the services of any Pemberton company. With respect to the United States, this website is directed only at major U.S. institutional investors”, or an investment adviser or a consultant acting on behalf of a major U.S. institutional investor, which is defined as a U.S. institutional investor or any other entity that owns or manages at least US$100 million in financial assets (“financial assets” include the securities of unaffiliated issuers, cash, money market instruments, futures and other derivative instruments).

Access to the information contained in this website is restricted under applicable U.S. federal and state securities laws. The securities of any fund or compartment of a fund have not been and will not be registered under the Securities Act or any state securities laws in the United States, and may not be offered or sold into, within the United States or to or for the account of any U.S. person except pursuant to an exemption from or in a transaction that is not subject to the registration requirements of the Securities Act or applicable state law.